Avycaz (Ceftazidime/Avibactam) Patent Expiration, LOE Window & CMS Spending
Avycaz (Ceftazidime/Avibactam) by AbbVie: FDA Orange Book core substance LOE 2032-06-15, 0 AB generics, $27.5M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N206494 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2032-06-15 |
| Last Listed Patent or Exclusivity Date | 2032-06-15 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $27.5M |
| 2024 Medicare Part D Spend | $19.5M |
| 2024 Medicaid Spend | $7.9M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 18.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.